Introduction
Bacteria belonging to the Burkholderia genus thrive in various ecological niches, ranging from the plant rhizosphere to the human lung, and play critical roles in ecological interactions oen through the secretion of specialised metabolites.
1,2 The metabolic arsenal of these bacteria is employed to eliminate other bacterial competitors and suppress plant pathogenic fungi and nematodes. In recent years various Burkholderia species have been shown to produce numerous specialised metabolites, many of which are assembled by polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs) biosynthetic assembly lines. 3 Notable examples include: the respiratory toxin bongkrekic acid; 4 anti-proliferative agents such as thailanstatin and spliceostatin; 5, 6 and the antibiotics enacyloxin IIa and gladiolin. 7, 8 Burkholderia participate in both antagonistic and mutualistic interactions with fungi. Much of the antagonistic behaviour can be attributed to an array of antifungal compounds secreted by many Burkholderia species. [9] [10] [11] [12] However, it has also been reported that Burkholderia strains have benecial effects on fungi, suggestive of symbiotic, or at least mutualistic interactions.
13-15
The exemplar study of this relationship is the symbiotic pairing of Burkholderia rhizoxinica (since reclassied as Paraburkholderia rhizoxinica) and the rice seedling blight pathogen Rhizopus microspores. B. rhizoxinica was identied as the producer of the antimitotic macrolide rhizoxin, the causative agent of rice seedling blight.
In a preliminary communication, we disclosed that Burkholderia gladioli isolates from cystic brosis (CF) patients produce icosalide A1 (1), 17 a lipopeptidiolide antibiotic originally isolated from a fungus. 18 We also showed that a nonribosomal peptide synthetase (NRPS) with an unusual architecture is responsible for icosalide A1 assembly.
17 Subsequently, Hertweck and co-workers reported that a B. gladioli endosymbiont of a beetle, along with several other Burkholderia species from diverse sources, also produce icosalide A1 and showed that an NRPS with the same unusual architecture as that identied in the CF isolates is responsible for its biosynthesis. 19 Here we provide a full account of our work and show that a B. gladioli strain containing the icosalide A1 NRPS is associated with the originally reported fungal producer. Moreover, we demonstrate that a chain-initiating condensation (C I ) domain embedded in the middle of the icosalide A1 NRPS selectively N-acylates a serinyl thioester covalently attached to the downstream peptidyl carrier protein (PCP) domain with a (3R)-3-hydroxydecanoyl panthetheine thioester, providing a mechanistic rationale for asymmetric lipopeptidiolide formation.
Results and discussion
We recently reported the discovery of gladiolin, a novel macrolide antibiotic with promising activity against Mycobacterium tuberculosis (MIC ¼ 0.4 mg mL À1 ) and low mammalian cell cytotoxicity, from B. gladioli BCC0238 (LMG-P26202). 7 In the course of investigations of other specialised metabolites produced by this CF clinical isolate using UHPLC-ESI-Q-TOF-MS, compounds with the molecular formulae C 36 H 64 N 4 O 10 and C 34 H 60 N 4 O 10 were observed (Fig S1 and S2 †) . These molecular formulae correspond to a set of three structurallyrelated lipopeptidiolides, known as icosalides A1 (1), A2 (2) and B (3), reported to be produced by fungi 18 (Fig. 1A) . The icosalides possess similar 20-membered lipopeptidiolide structures consisting of two serine, leucine and 3-hydroxy acid residues. In icosalide A1 (1), one of the leucine residues is D-congured, whereas all of the amino acid residues in icosalides A2 (2) and B (3) are L-congured. Icosalides A1 (1) and A2 (2) both contain one eight-carbon and one ten-carbon 3-hydroxy acid residue, whereas icosalide B (3) contains two eightcarbon 3-hydroxy acid residues. The incorporation of a D-leucine residue into icosalide A1 (1) has a dramatic effect on its biological activity. While icosalide A1 (1) is active against Streptococcus pyogenes (MIC: 8-16 mg mL À1 ), icosalides A2 (2) and B (3) do not show any antibacterial activity but are cytotoxic towards replicating MDCK cells (CC 50 : 5 mg mL À1 ).
18
The compound with the molecular formula C 36 H 64 N 4 O 10 was puried using semi-preparative HPLC and its planar structure was shown to be identical to that of icosalide A1 (1) using a combination of 1 H, 13 C and HMBC NMR experiments ( Fig. S3 and Table S1 †). The absolute stereochemistry of the amino acid residues in the puried compound was determined via saponication of the esters, followed by semi-preparative HPLC purication and MS analysis of the resulting pair of 3-hydroxyacyl-dipeptides, acid hydrolysis to liberate the constituent amino acids, derivatisation using Marfey's reagent and comparison with the corresponding L and D-congured leucine and serine standards ( Fig. S4 and S5 †). This revealed that the Leu-2 residue is D-congured, conrming the identity of the metabolite produced by B. gladioli as icosalide A1 (1). The production level of the compound with the molecular formula C 34 H 60 N 4 O 10 was too low to permit characterisation by NMR spectroscopy (Fig. S6 †) , but it seems likely that this has the same planar structure as icosalide B (3). The activity of puried icosalide A1 (1) against several Gram-positive and Gramnegative bacteria, including the ESKAPE panel of pathogens, and Candida albicans was tested. Modest activity against E. faecium (MIC: 16 mg mL À1 ) was observed (Table S2 †) .
Inspection of putative specialised metabolite biosynthetic gene clusters in the previously reported genome sequence of B. gladioli BCC0238, 7 identied a single $15 kb gene (icoA) on chromosome 2 encoding a nonribosomal peptide synthetase (NRPS) with the requisite module and domain organisation for icosalide assembly (Fig. 1B) . This NRPS contains four adenylation (A) domains, two of which are predicted to be specic for Lleucine and two for L-serine 20 (Table S3 †) . It also contains ve condensation (C) domains and a thioesterase (TE) domain, which together account for the four amide and two ester bondforming reactions required to assemble the lipopeptidiolide structure of the icosalides 21 ( Fig. 2A) . We identied icoA in the genomes of several other B. gladioli isolates (BCC0252, BCC1677, BCC1698 and BCC1720), all of which were shown to produce icosalide A1 (1). In contrast, no icosalide A1 (1) production was detected in B. gladioli BCC1713 (Fig. S7 †) , which is lacking icoA. These data are consistent with the hypothesis that the NRPS encoded by icoA is responsible for icosalide biosynthesis. To verify this, we inactivated the icoA gene in B. gladioli BCC0238 using insertional mutagenesis. UHPLC-ESI-Q-TOF-MS analysis of extracts from the icoA mutant conrmed that it is no longer able to produce icosalides (Fig. 1C) .
Icosalide A1 (1) was originally isolated from extracts of an Aureobasidium species fungus (strain MSX 59166), whereas icosalides A2 (2) and B (3) were isolated from a second less well characterized fungal species (MSX 74159). 18 The data presented above suggested that B. gladioli bacteria associated with these fungi might be the true producers of the icosalides isolated from them. To investigate this hypothesis, total DNA from the originally reported icosalide A1 (1) producer, Aureobasidium sp. MSX 59166, was screened by PCR for orthologues of icoA and the bacterial housekeeping gene recA. In both cases, we obtained amplimers of the expected size (Fig. S8 †) , conrming that a bacterium, likely harbouring an icoA orthologue, is associated with the fungus. Burkholderia species can be unambiguously identied via phylogenetic comparison of their recA sequences. 22 Thus, we compared the sequence of the recA amplimer with the sequences of recA genes from 25 representative Burkholderia species. This showed that the Aureobasidiumassociated bacterium is B. gladioli (Fig. 1D) . Illumina sequencing of the total DNA from the Aureobasidium sp. allowed an approximately 1 Mb contiguous sequence of bacterial DNA, encompassing the icoA orthologue, to be assembled (Fig. S9 †) .
Comparison of this contiguous sequence with the corresponding region of the B. gladioli BCC0238 genome showed a high degree of synteny (Fig. S9 †) , conrming that the Aureobasidium sp. harbours a B. gladioli strain containing an icoA orthologue. Although a Gram-negative bacterium could be isolated from the Aureobasidium sp., it quickly lost viability and was not identiable.
Inspection of the structure of icosalide A1 (1) suggests it is assembled via initial formation of 3-hydroxyoctanoyl-D-leucinyl-L-serinyl and 3-hydroxydecanoyl-L-serinyl-L-leucinyl thioesters, which are joined via a pair of ester linkages to form the lipopeptidiolide. To gain insight into the role played by each of the ve C domains of IcoA in the biosynthesis of icosalide A1 (1), we carried out phylogenetic analyses. 23 These indicated that the rst and fourth domains group with chain initiating (C I ) domains, which are typically located at the N-terminus of the rst module in NRPSs responsible for lipopeptide biosynthesis and initiate chain assembly via N-acylation of the amino acyl thioester bound to the downstream PCP domain with a fatty acyl thioester. The third and h C domains of IcoA belong to the L C L group, which catalyse formation of a peptide bond between L-congured amino acyl thioesters attached to the upstream and downstream PCP domains. In contrast, the second C domain of IcoA clusters with bifunctional epimerisationcondensation (C E ) domains, which catalyse epimerisation of the a-carbon in the aminoacyl thioester attached to the upstream PCP domain, followed by condensation of the resulting D- (Fig. 2) . The C I domain appended to the N-terminus of module 1 initiates chain assembly via N-acylation of the L-leucinyl thioester attached to the module 1 PCP domain with a 3-hydroxyoctanoyl thioester, likely donated by the primary metabolic fatty acid synthase (FAS). The C-domain in module 2 then catalyses epimerisation of the resulting N-acyl-leucinyl thioester, followed by condensation with the L-serinyl thioester attached to the module 2 PCP domain. Module 3 of IcoA is very unusual, because it contains an L C L domain directly followed by a C I domain. We hypothesize that the C I domain in this module catalyses a second chain initiation event, resulting in N-acylation of the L-serinyl thioester attached to the downstream PCP domain with a 3-hydroxydecanoyl group, again likely provided by the primary metabolic FAS. The L C L domain then catalyses acylation of the hydroxyl group in the resulting 3-hydroxydecanoyl-L-serinyl thioester with the 3-hydroxyoctanoyl-D-leucinyl-L-serinyl thioester attached to the module 2 PCP domain.
Elongation of the resulting intermediate with the L-leucinyl thioester attached to the PCP domain in module 4, catalysed by the upstream L C L domain, followed by lactonisation catalysed by the downstream TE domain, yields icosalide A1 (Fig. 2) .
To the best of our knowledge, initiation of chain assembly by an embedded C I domain like the one found in module 3 of IcoA is without precedent in NRPS enzymology. We thus sought to experimentally validate the proposed chain initiation reaction in vitro by overproducing the C I -A-PCP tri-domain from module 3 of IcoA in E. coli. The resulting N-terminal His 6 fusion protein, was puried to homogeneity using immobilised metal-ion affinity chromatography and the hexahistidine tag was cleaved using thrombin (Fig. S10 †) . ESI-Q-TOF-MS analysis showed that the PCP domain of this protein had been partially converted to the holo form by an E. coli phosphopantetheinyl transferase (Fig. S10 †) . To fully convert the PCP domain into the holo form we incubated the protein with puried recombiant Sfp, a substrate tolerant phosphopantetheinyl transferase from B. subtilis, 24 and coenzyme A. The holo-C I -A-PCP tri-domain was incubated with ATP, L-Ser and 3R-congured 3-hydroxyoctanoyl or 3-hydroxydecanoylpanthetheine thioesters, which mimic the (3R)-3-hydroxyoctanoyl and (3R)-3-hydroxydecanoyl-ACP intermediates in fatty acid biosynthesis proposed to be intercepted by the C I domains in modules 1 and 3, respectively, of the NRPS. UHPLC-ESI-Q-TOF-MS analysis of the C I -A-PCP tri-domain showed mass shis consistent with the formation of serinyl, 3-hydroxyoctanoyl-serinyl and 3-hydroxydecanoyl-serinyl PCPthioesters (Fig. 3) . When the C I -A-PCP tri-domain was replaced with a mutant containing an Ala residue in place of the active site His residue in the C I domain, only trace amounts of products were formed (Fig. 3) .
Icosalide A1 contains an N-((3R)-3-hydroxydecanoyl)-L-serine residue. 19 The module 3 C I domain is thus expected to accept 3-hydroxydecanoyl thioesters in preference to 3-hydroxyoctanoyl thioesters. To test this hypothesis, we incubated the holo-C I -A-PCP tri-domain with ATP, L-Ser and equimolar mixture of the 3R-congured 3-hydroxyoctanoyl and 3-hydroxydecanoylpanthetheine thioesters. UHPLC-ESI-Q-TOF-MS analysis showed that only the product resulting from condensation with the 10-carbon thioester is formed (Fig. 3) . The incorporation of 3-hydroxyoctanoyl-L-serinyl-L-leucine into icosalide A2 (2), the major icosalide produced by the MSX 74159 fungus, suggests that the NRPS responsible for assembly of this metabolite contains an embedded C I domain with a preference for 8-carbon thioesters. It would therefore be interesting to investigate the mechanisms underlying icosalide A2 biosynthesis.
The module 3 C I domain might also be expected to prefer Rcongured 3-hydroxyacyl thioesters to their S-congured counterparts. (Note, however, that the ketoreductase in bacterial fatty acid biosynthesis produces exclusively 3R-congured 3-hydroxyacyl-ACP thioester intermediates. 25 There may therefore be no selective pressure to drive the evolution of stereoselectivity in C I domains.) To investigate whether the module 3 C I domain is stereoselective, we incubated the holo-C I -A-PCP tridomain with ATP, L-Ser and (3S)-3-hydroxyoctanoyl or (3S)-3-hydroxydecanoyl-panthetheine thioesters. Although the L C L , condensation domain that catalyses condensation of L-configured aminoacyl donor and acceptor substrates; PCP, peptidyl carrier protein domain; TE, thioesterase domain. The residues used to predict the substrate specificity of Adomains are shown in Table S3 †. reaction with the 10-carbon thioester resulted in a signicant degree of product formation, it was clearly less efficient than the reaction with the corresponding 3R-congured thioester (Fig.  3) . In contrast, only trace amounts of product were formed in the reaction employing the eight-carbon thioester (Fig. 3) . Thus, the C I domain appears to possess a moderate to high degree of stereoselectivity, depending on the carbon chain length of the substrate. Overall, our data show that the module 3 C I domain of IcoA plays a key role in initiating the assembly of the (3R)-3-hydroxydecanoyl-L-serinyl-L-leucinyl moiety of icosalide A1.
Conclusions
We have shown that the "fungal" antibiotic icosalide A1 (1), originally isolated from an Aureobasidium sp., is produced by a B. gladioli strain closely associated with the fungus. In addition, we have shown that B. gladioli isolates from a range of sources, including CF lung infections, mushroom rot and insects also produce this metabolite. Comparative genome sequence analysis coupled with genetic manipulation allowed identication of a gene encoding the NRPS responsible for icosalide A1 biosynthesis. The third module of this NRPS has a very unusual architecture, containing a putative chain-initiating C I domain in addition to a chain elongating L C L domain. Intact protein mass spectrometry showed that this C I domain catalyses selective Nacylation of a serinyl thioester bound to the module 3 PCP domain with a (3R)-3-hydroxydecanoyl thioester. Thus, the asymmetric lipopeptidiolide core of icosalide A1 (1) is assembled by a unique mechanism involving two distinct chain initiation events on a single NRPS subunit.
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